Published on April 5, 2021 – 06:41 GMT 
MDimune and Evercyte form partnership for developing tumor-targeting EVs
SEONGDONG-GU, SEOUL, SOUTH KOREA, April 5, 2021 /EINPresswire.com/ — MDimune Inc. and Evercyte GmbH announced a strategic collaboration to develop tumor-targeted drug delivery by combining MDimune’s BioDrone® platform technology based on cell-derived …
Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry …
